Transcription factors as drug targets in cancer

European Journal of Cancer Part A

Volumn 32, Issue 11, 1996, Pages 1857-1863

  Hurst, H C ^a  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

Cancer therapy; Transcription factors

Indexed keywords

TRANSCRIPTION FACTOR;

CANCER THERAPY; DRUG TARGETING; HUMAN; ONCOGENE; PRIORITY JOURNAL; REVIEW;

EID: 0030271751     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/0959-8049(96)00214-6     Document Type: Review

References (41)

1. 1. Zawel L, Reinberg D. Common themes in assembly and function of eucaryotic transcription complexes. Ann Rev Biochem 1995, 64, 533-561.
2. 2. Muller R. Transcription factors and mammalian development. Trends Genetics 1995, 11, 173-178.
3. 3. Lobe CG. Transcription factors and mammalian development. Curr Topics Dev Biol 1992, 27, 351-383.
4. 4. Triezenberg SJ. Structure and function of transcriptional activation domains. Curr Opin Genet Dev 1995, 5, 190-196.
5. 5. Burley SK, Roeder RG. Activators of transcription. Ann Rev Biochem 1996, 65, 769-799.
6. 6. Cowell IG. Repression versus activation in the control of gene transcription. Trends Biochem Sci 1994, 19, 38-42.
7. 7. Guarente L. Transcriptional coactivators in yeast and beyond. Trends Biochem Sci 1995, 20, 517-521.
8. 8. Karin M, Hunter T. Transcriptional control by protein phosphorylation - signal transsmission from the cell-surface to the nucleus. Curr Biol 1995, 5, 747-757.
9. 9. Rippe K, Vonhippel PH, Langowski J. Action at a distance - DNA looping and initiation of transcription. Trends Biochem Sci 1995, 20, 500-506.
10. 10. Struhl K. Chromatin structure and RNA polymerase II connection: implications for transcription. Cell 1996, 84, 179-182.
11. 11. Wolffe AP, Pruss D. Targeting chromatin disruption; transcription regulators that acetylate histones. Cell 1996, 84, 817-819.
12. 12. Wolffe AP. Insulating chromatin. Curr Biol 1994, 4, 85-87.
13. 13. Tijan R, Maniatis T. Transcriptional activation: a complex puzzle with few easy pieces. Cell 1994, 77, 5-8.
14. 14. Wemer MH, Gronenborn AM, Clore GM. Intercalation, DNA kinking, and the control of transcription. Science 1996, 271, 778-784.
15. 15. Huang JC, Zamble DB, Reardon JT, Lippard SJ, Sancar A. HMG-domain proteins specifically inhibit the repair of the major DNA adduct of the anticancer drug cisplatin by human excision nuclease. Proc Natl Acad Sci USA 1994, 91, 10394-10398.
16. 16. Kane SA, Lippard SJ. Photoreactivity of platinum(II) in cisplatin-modified DNA affords specific cross-links to HMG domain proteins. Biochemistry 1996, 35, 2180-2188.
17. 17. Hill CS, Treisman R. Transcriptional regulation by extracellular signals: mechanisms and specificity. Cell 1995, 80, 199-211.
18. 18. Kopp E, Ghosh S. Inhibition of NF-κB by sodium salicylate and aspirin. Science 1994, 265, 956-959.
19. 19. Butt TR, Karathanasis SK. Transcription factors as drug targets: opportunities for therapeutic selectivity. Gene Expression 1995, 4, 319-336.
20. 20. Beato M, Herrich P, Schutz G. Steroid hormone receptors: many actors in search of a plot. Cell 1995, 83, 851-857.
21. 21. Wyatt MD, Garbiras BJ, Lee M, Forrow SM, Hartley JA. Synthesis and DNA-binding properties of a series of n to c linked and imidazole-containing analogs of distamycin. Bioorg Medicinal Chem Letts 1994, 4, 801-806.
22. 22. Wyatt MD, Lee M, Garbiras BJ, Souhami RL, Hartley JA. Sequence specificity of alkylation for a series of nitrogen mustard-containing analogs of distamycin of increasing binding-site size - evidence for increased cytotoxicity with enhanced sequence specificity. Biochemistry 1995, 34, 13034-13041.
23. 23. Bourdouxhe C, Colson P, Houssier C, et al. Design of composite drug molecules - mutual effects on binding to DNA of an intercalator, amsacrine, and a minor-groove binder, netropsin. Anticancer Drug Des 1995, 10, 131-154.
24. 24. Helene C. Control of gene expression by modified oligonucleotides. Anticancer Drug Des 1991, 6, 569-584.
25. 25. Gee JE, Revankar GR, Rao TS, Hogan ME. Tripler formation at the rat neu gene utilizing imidazole and 2′-deoxy-6-thioguanosine base substitutions. Biochemistry 1995, 34, 2042-2048.
26. 26. Okada T, Yamaguchi K, Yamashita J. Triplex-forming oligonucleotide binding represses transcription of the human c-erbB gene in glioma. Growth Factors 1994, 11, 259-270.
27. 27. Nielson PE, Egholm M, Berg RH, Buchardt O. Sequence-selective recognition of DNA by strand displacement with a thymine substituted polyamide. Science 1991, 254, 1497-1500.
28. 28. Bielinska A, Shivdasani RA, Zhang L, Nabel GJ. Regulation of gene expression with double-stranded phosphorothioate oligonucleotides. Science 1990, 250, 997-1000.
29. 29. Parker MG. Action of pure antiestrogens in inhibiting estrogen-receptor action. Breast Cancer Res Treat 1993, 26, 131-137.
30. 30. Fanjul A, Dawson MI, Hobbs PD, et al. A new class of retinoids, with selective inhibition of AP-1, inhibits proliferation. Nature 1994, 372, 107-111.
31. 31. Nagpal S, Athanikar J, Chandraratna RA. Separation of transactivation and AP1 antagonism functions of retinoic acid receptor alpha. J Biol Chem 1995, 270, 923-927.
32. 32. Chen JY, Penco S, Ostowski J, et al. Rar-specific agonist/antagonists which dissociate transactivation and ap1 transrepression inhibit anchorage-independent cell-proliferation. EMBO J 1995, 14, 1187-1197.
33. 33. Chomienne C, Ballerini P, Balitrand N, et al. All-trans retinoic acid in acute promyelocytic leukemias. II. In vitro studies: structure-function relationship. Blood 1990, 76, 1704-1709.
34. 34. Gillard EF, Solomon E. Acute promyelocytic leukemia and the t(15-17) translocation. Semin Cancer Biol 1993, 4, 359-368.
35. 35. Rabbitts TH. Chromosomal translocations in human cancer. Nature 1994, 372, 143-149.
36. 36. Hupp TR, Sparks A, Lane DP. Small peptides activate the latent sequence-specific DNA binding function of p53. Cell 1995, 83, 237-245.
37. 37. Hynes NE, Stern DF. The biology of erbB-2/neu her-2 and its role in cancer. BBA Rev Cancer 1994, 1198, 165-175.
38. 38. Hollywood DP, Hurst HC. A novel transcription factor, OB2-1, is required for overexpression of the protooncogene c-erbB-2 in mammary-tumor lines. EMBO J 1993, 12, 2369-2375.
39. 39. Bosher JM, Williams T, Hurst HC. The developmentally-regulated transcription factor AP-2 is involved in c-erbB-2 overexpression in human mammary-carcinoma. Proc Natl Acad Sci USA 1995, 92, 744-747.
40. 40. Hollywood DP, Hurst HC. Targeting gene-transcription - a new strategy to down-regulate c-erbB-2 expression in mammary-carcinoma. Br J Cancer 1995, 71, 753-757.
41. 41. Noonberg SB, Scott GK, Hunt A, Hogan ME, Benz CC. Inhibition of transcription factor binding to the HER2 promoter by triplex-forming oligonuleotides. Gene 1994, 149, 123-126.